NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) Q1 2026 Deepening Losses Test Bullish Revenue Growth Narrative
Kymera Therapeutics Q1 2026 earnings snapshot
Kymera Therapeutics (KYMR) has kicked off Q1 2026 with the market watching closely after recent quarters that paired modest revenue with sizeable losses, including Q4 2025 revenue of US$2.9 million and a basic EPS loss of US$0.97 on net income excluding extra items of a US$87 million loss. Over the past year, the company has seen quarterly revenue range from US$2.8 million to US$22.1 million, while basic EPS losses moved between US$0.82 and...